Costimulation couture: A designer approach to regulating autoimmunity

Journal of Clinical Investigation

Volumn 116, Issue 8, 2006, Pages 2080-2083

  Ansari, Mohammed Javeed ^a   Sayegh, Mohamed H ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Transplantation Biology Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; BISPECIFIC ANTIBODY; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYBRID PROTEIN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; DIABETES MELLITUS; GENE THERAPY; HOMEOSTASIS; IMMUNE RESPONSE; LYMPHOID TISSUE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYROIDITIS; TRANSPLANTATION;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; DIABETES MELLITUS; HUMANS; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES;

EID: 33746681289     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29455     Document Type: Review

References (41)

1. Bretscher, P., and Cohn, M. 1970. A theory of self-nonself discrimination. Science. 169:1042-1049.
2. Lafferty, K.J., and Woolnough, J. 1977. The origin and mechanism of the allograft reaction. Immunol. Rev. 35:231-262.
3. Lafferty, K.J., Prowse, S.J., Simeonovic, C.J., and Warren, H.S. 1983. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu. Rev. Immunol. 1:143-173.
4. June, C.H., Ledbetter, J.A., Linsley, P.S., and Thompson, C.B. 1990. Role of the CD28 receptor in T-cell activation. Immunol. Today. 11:211-216.
5. Harding, F.A., McArthur, J.G., Gross, J.A., Raulet, D.H., and Allison, J.P. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 356:607-609.
6. Walunas, T.L., et al. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1:405-413.
7. Krummel, M.F., and Allison, J.P. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:459-465.
8. Eggena, M.P., et al. 2004. Cooperative roles of CTLA-4 and regulatory T cells in tolerance to an islet cell antigen. J. Exp. Med. 199:1725-1730.
9. Read, S., Malmstrom, V., and Powrie, F. 2000. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 192:295-302.
10. Takahashi, T., et al. 2000. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192:303-310.
11. Bluestone, J.A., and Abbas, A.K. 2003. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3:253-257.
12. Tang, Q., et al. 2004. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur. J. Immunol. 34:2996-3005.
13. Zheng, S.G., et al. 2006. TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J. Immunol. 176:3321-3329.
14. Salomon, B., et al. 2000. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 12:431-440.
15. Perez, V.L., et al. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 6:411-417.
16. Bluestone, J.A. 1997. Is CTLA-4 a master switch for peripheral T cell tolerance? J. Immunol. 158:1989-1993.
17. Markees, T.G., et al. 1998. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-γ, and CTLA4. J. Clin. Invest. 101:2446-2455.
18. Judge, T.A., et al. 1999. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J. Immunol. 162:1947-1951.
19. Greenwald, R.J., Boussiotis, V.A., Lorsbach, R.B., Abbas, A.K., and Sharpe, A.H. 2001. CTLA-4 regulates induction of anergy in vivo. Immunity. 14:145-155.
20. Bluestone, J.A., St. Clair, E.W., and Turka, L.A. 2006. CTLA4Ig: bridging the basic immunology with clinical application. Immunity. 24:233-238.
21. Rothstein, D.M., and Sayegh, M.H. 2003. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol. Rev. 196:85-108.
22. Genovese, M.C., et al. 2005. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353:1114-1123.
23. Vincenti, F., et al. 2005. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353:770-781.
24. Fife, B.T., Griffin, M.D., Abbas, A.K., Locksley, R.M., and Bluestone, J.A. 2006. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J. Clin. Invest. 116:2252-2261. doi:10.1172/JCI27856.
25. Luhder, F., Hoglund, P., Allison, J.P., Benoist, C., and Mathis, D. 1998. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. 187:427-432.
26. Khoury, S.J., and Sayegh, M.H. 2004. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity. 20:529-538.
27. Greenwald, R.J., Freeman, G.J., and Sharpe, A.H. 2005. The B7 family revisited. Annu. Rev. Immunol. 23:515-548.
28. Ansari, M.J., et al. 2003. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198:63-69.
29. Salama, A.D., et al. 2003. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198:71-78.
30. Guleria, I., et al. 2005. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J. Exp. Med. 202:231-237.
31. Keir, M.E., et al. 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203:883-895.
32. Egen, J.G., and Allison, J.P. 2002. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity. 16:23-35.
33. Chikuma, S., Imboden, J.B., and Bluestone, J.A. 2003. Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 197:129-135.
34. Griffin, M.D., et al. 2000. Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J. Immunol. 164:4433-4442.
35. Rao, S., et al. 2001. Targeted delivery of anti-CTLA-4 antibody downregulates T cell function in vitro and in vivo. Clin. Immunol. 101:136-145.
36. Vasu, C., Gorla, S.R., Prabhakar, B.S., and Holterman, M.J. 2003. Targeted engagement of CTLA-4 prevents autoimmune thyroiditis. Int. Immunol. 15:641-654.
37. Fecteau, S., et al. 2001. CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nat. Immunol. 2:58-63.
38. Ariyan, C., et al. 2003. Cutting edge: transplantation tolerance through enhanced CTLA-4 expression. J. Immunol. 171:5673-5677.
39. Salvalaggio, P.R., et al. 2006. Antigen exposure during enhanced CTLA-4 expression promotes allograft tolerance in vivo. J. Immunol. 176:2292-2298.
40. Vijayakrishnan, L., et al. 2004. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity. 20:563-575.
41. Yolcu, E.S., Askenasy, N., Singh, N.P., Cherradi, S.E., and Shirwan, H. 2002. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity. 17:795-808.